ASTERDM - Aster DM Healthcare Limited Share Price

In the earnings call held on May 1, 2026, Aster DM Healthcare management provided a positive outlook, particularly focusing on the anticipated merger with Quality Care and its implications for operational performance and growth.

The combined proforma performance of Aster and Quality Care revealed an 18% year-on-year revenue growth for Q4 FY26, reaching INR 2,361 crores. Total patient volumes increased by 12%, and average revenue per patient (ARPP IP) improved by 8%. Operating EBITDA grew by 25% to INR 517 crores, resulting in margins of 21.9% and a return on capital employed (ROCE) improvement of 293 basis points to 21.1%.

For the full fiscal year 2026, combined revenues accumulated to INR 9,273 crores, which is a 14% increase year-on-year. Operating EBITDA reached INR 2,013 crores, translating to margins of 21.7%. Over the past three years, the combined entity exhibited a revenue CAGR of 14.5% and EBITDA CAGR of nearly 20%.

Management highlighted a disciplined capacity expansion approach, adding 373 beds over the past year, taking total capacity to over 10,620 beds, with plans for an additional 4,445 beds which could elevate total capacity beyond 15,000 beds. The merger with Quality Care received overwhelming support from shareholders (96.7% approval) and was progressing towards NCLT for final approval, with completion expected within the current quarter.

Forward-looking points include a commitment to adding nearly 2,500 beds in the next few years, focusing on capital-efficient brownfield and greenfield projects. The management also emphasized continuous efforts to enhance patient care through clinical excellence, operational efficiency, and talent acquisition, aimed at sustainable long-term growth.

1. Question: "Can you tell us where the industry currently stands with the common insurance and empanelment with private insurers and do you see this as a threat for private hospitals?"

Answer: "The empanelment piece has been in play for a while, but we haven't signed up for it at QCIL or Aster, nor have large hospitals. Concerns around data privacy and transparency remain. If adopted, it could drive costs down for empanelment, but currently, there's no coercive push; acceptance depends on private hospitals."

2. Question: "What is the current status of MVT patients in Kerala after Ramadan, and how are you addressing the inflow?"

Answer: "Despite some drops from the Middle East, MVT has grown 41% year-on-year. We've mitigated losses by attracting more patients from the Maldives and African countries. The continual focus there ensures steady patient flow as we expand our coverage."

3. Question: "What are the key initiatives supporting Aster's current momentum in ARPOB and IP volumes?"

Answer: "We are strengthening processes like doctor engagement and OP-IP conversion. Moreover, we added over 36 new doctors in the last six months, which is crucial for maintaining growth momentum across our clusters, especially as we aim to improve the CONGO mix from 55% to 65%."

4. Question: "Can you elaborate on the current performance and potential of the Aster Whitefield unit, particularly regarding its occupancy and EBITDA margins?"

Answer: "Aster Whitefield currently has a 60% occupancy. With planned expansions, including an additional 159 beds, we expect EBITDA margins to improve to mid-20s over time as we enhance our service offerings and grow patient volumes significantly."

5. Question: "What are QCIL's long-term expansion plans and per bed capex estimates for brownfield and greenfield projects?"

Answer: "We're planning to add around 1,700 beds, primarily through brownfield expansion. Per bed capex will be approximately INR 0.8-1.0 crores for brownfield and INR 1.5 crores for greenfield projects, with investments focused on enhancing clinical capabilities across our assets."